MedTrace Logo

Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects

NCT05508204 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-01-11

No results posted yet for this study

Summary

Phase 1, open-label study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic of multiple doses of BION-1301 in Japanese healthy subjects.

Conditions

  • Healthy Volunteer

Interventions

DRUG

BION-1301

A solution for SC injection administered as a single dose

Sponsors & Collaborators

  • Chinook Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Charlotte Jones-Burton, M.D. · Chinook Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-19
Primary Completion
2022-12-16
Completion
2022-12-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05508204 on ClinicalTrials.gov